[18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer.

Francesco PasqualettiMarco PanichiMartina SolliniAldo SainatoLuca GalliRiccardo MorgantiSerena ChiacchioAndrea MarcianoRoberta ZancaLorenzo MannelliGabriele CoraggioAndrea SbranaPaola CocuzzaSabrina MontroneDavide BaldacciniAlessandra GonnelliAlessandro MolinariMartina CantarellaValentina MazzottiSergio RicciFabiola PaiarPaola Anna Erba

Published in: European journal of nuclear medicine and molecular imaging (2019)

Based on our findings, [18F]FMCH PET/CT can identify oligometastatic prostate cancer patients suitable for SBRT, resulting in a systemic therapy-free survival of 39.1 months.

Keyphrases

pet ct
prostate cancer
free survival
radiation therapy
radical prostatectomy
early stage
positron emission tomography
locally advanced
radiation induced
computed tomography
squamous cell carcinoma
cell therapy
smoking cessation
drug induced